4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 81 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $53,066,498 | -28.8% | 2,528,180 | +8.0% | 0.00% | 0.0% |
| Q1 2024 | $74,550,584 | +97.1% | 2,339,943 | +25.3% | 0.00% | 0.0% |
| Q4 2023 | $37,822,361 | +56.2% | 1,866,849 | -1.9% | 0.00% | 0.0% |
| Q3 2023 | $24,218,405 | -32.1% | 1,902,467 | -3.6% | 0.00% | 0.0% |
| Q2 2023 | $35,653,952 | +34.2% | 1,973,102 | +27.6% | 0.00% | 0.0% |
| Q1 2023 | $26,573,745 | -6.0% | 1,545,884 | +21.5% | 0.00% | 0.0% |
| Q4 2022 | $28,255,785 | +166.1% | 1,272,210 | -3.6% | 0.00% | – |
| Q3 2022 | $10,617,000 | +15.1% | 1,320,362 | -0.1% | 0.00% | – |
| Q2 2022 | $9,228,000 | -52.7% | 1,322,149 | +2.4% | 0.00% | – |
| Q1 2022 | $19,519,000 | -30.7% | 1,290,941 | +0.6% | 0.00% | -100.0% |
| Q4 2021 | $28,152,000 | +10.3% | 1,283,083 | +35.6% | 0.00% | 0.0% |
| Q3 2021 | $25,513,000 | +125.3% | 945,977 | +101.2% | 0.00% | – |
| Q2 2021 | $11,325,000 | -40.3% | 470,276 | +7.6% | 0.00% | -100.0% |
| Q1 2021 | $18,969,000 | +4481.9% | 437,262 | +4272.6% | 0.00% | – |
| Q4 2020 | $414,000 | – | 10,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |